Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Oncology | Pediatrics | Pharmacy | Conference News

Back to Journal Articles

ASCO: Crizotinib Tolerated, Active in Pediatric Patients

Last Updated: May 18, 2012.

 

Crizotinib active in anaplastic large cell lymphoma; neuroblastoma; other tumors with ALK mutations

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For pediatric patients with tumors that have genetic aberrations in the anaplastic lymphoma kinase gene, crizotinib is well tolerated and has antitumor activity, according to a study released May 16 in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

FRIDAY, May 18 (HealthDay News) -- For pediatric patients with tumors that have genetic aberrations in the anaplastic lymphoma kinase (ALK) gene, crizotinib is well tolerated and has antitumor activity, according to a study released May 16 in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

Yael P. Mosse, M.D., from the Children's Hospital of Philadelphia, and colleagues conducted a phase 1 dose-escalation and pharmacokinetic trial of crizotinib in 70 patients with refractory solid tumors and anaplastic large cell lymphoma (ALCL). In part A1, patients were assigned to one of six dose levels of crizotinib; in part A2, patients with confirmed ALK fusion proteins, mutations, or amplifications were enrolled at one dose level lower than A1; and those with neuroblastoma were enrolled on a separate stratum (A3).

Of the 70 patients enrolled, the researchers found that 57 were fully evaluable for toxicity: 29 in A1, 18 in A2, and 10 in A3. In A1, two of seven patients developed dose-limiting toxicity at 215 mg/m² and one of six at 365 mg/m². In A2, there was one case of dose-limiting toxicity at 165 mg/m². Seven of eight patients with ALCL demonstrated a complete response. Two patients with neuroblastoma had a complete response, including one with a documented ALK mutation. Partial responses were experienced by one patient with an inflammatory myofibroblastic tumor and one with non-small-cell lung cancer.

"It's remarkable that this targeted oral medication provided such a substantial benefit in these children with highly aggressive cancers, most of whom had already undergone every available therapy," Mosse said in a statement. "Now that we know more about the drivers of some pediatric cancers, we can target those changes and treat patients in a much smarter, and potentially safer, way."

One of the authors disclosed financial ties to Pfizer, which manufactures crizotinib.

Abstract
More Information

Copyright © 2012 HealthDay. All rights reserved.


Previous: Adjuvant Radiochemotherapy Has Lasting Benefit in Gastric Cancer Next: Recurrent HTN Seen for Half of Women With HTN in Pregnancy

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.